Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq:CSTL) announced that executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. ET. A live audio webcast and replay will be accessible via the company’s website.
Castle Biosciences (Nasdaq:CSTL) announced that its AdvanceAD-Tx test won the 2026 MedTech Breakthrough Genomics Innovation Award, the company’s fifth MedTech Breakthrough honor.
AdvanceAD-Tx is a clinically validated, non-invasive gene expression profile test guiding systemic treatment selection for patients 12+ with moderate-to-severe atopic dermatitis, supported by prospective multi-center data on skin clearance and symptom relief.
Castle Biosciences (Nasdaq: CSTL) reported Q1 2026 revenue of $83.7 million and raised full-year 2026 revenue guidance to $345–355 million from $340–350 million. Core test reports (DecisionDx-Melanoma, TissueCypher) grew 36% year-over-year; DecisionDx-Melanoma test reports were 10,021.
Gross margin was 73% (Adjusted Gross Margin 76%), adjusted EBITDA was a $5.1 million loss, and cash plus investments totaled $261.7 million as of March 31, 2026.
Castle Biosciences (Nasdaq: CSTL) is supporting nationwide patient advocacy, community screenings and education throughout May for Skin Cancer Awareness Month. Activities include advocacy walks, symposiums at Fred Hutch, Ohio State (May 9) and Yale (May 12), a May 26 webinar, Sun Bus skin checks (May 15–16) and participation in Nevada’s Biggest Little Skin Check (May 14).
The company partners with AIM at Melanoma, Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus to expand access to early detection and patient education.
Castle Biosciences (NASDAQ:CSTL) announced Mayo Clinic data presented at DDW 2026 showing the TissueCypher test refines risk stratification and informs risk-aligned surveillance for Barrett's esophagus.
In multicenter cohorts, physicians changed surveillance intervals in 55% of patients and aligned recommendations with TissueCypher risk in 79%; TissueCypher classified 84% as low risk versus 38% by a clinical model (κ=0.04).
Castle Biosciences (Nasdaq: CSTL) will present new DecisionDx-Melanoma data at EADO (Apr 23-25, 2026) and ACMS (Apr 30–May 3, 2026).
Multi-center and SEER population analyses show the 31-gene expression profile provides prognostic information beyond AJCC staging, identifying higher-risk patients among thin and early-stage melanoma who may benefit from intensified management.
Castle Biosciences (Nasdaq: CSTL) will release first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. Management will host a live webcast at 4:30 p.m. ET the same day with a brief Q&A following commentary.
Investors can access the live webcast at the provided events link or via the company's Investor Relations webcast page; a replay will be available after the presentation.
Castle Biosciences (Nasdaq: CSTL) announced it received the 2026 USA TODAY Top Workplaces USA Award on April 10, 2026, marking its fifth consecutive year on the list. The award recognizes organizations with 150+ employees based solely on confidential employee survey feedback.
The program is run by Energage and USA TODAY and measures workplace experience themes tied to high performance; the full 2026 Top Workplaces USA list is available on TopWorkplaces.com.
Castle Biosciences (Nasdaq: CSTL) will present SEER-linked data at AAD 2026 showing that the DecisionDx-Melanoma 31-gene expression profile significantly stratifies five-year melanoma-specific survival within AJCC stages and T categories.
In 1,868 patients (2013–2019), Class 1A versus 2B outcomes differed markedly (T1: 96.7% vs 70.0%; Stage IIB–III: 87.4% vs 48.5%), supporting more personalized, risk-aligned management.
Castle Biosciences (Nasdaq: CSTL) published a prospective multicenter study in Future Oncology showing DecisionDx-Melanoma’s i31-SLNB identifies patients below the NCCN 5% threshold for forgoing SLNB. Key results: 2.6% observed SLN positivity overall for 5% predicted patients; in T1b–T2a; 97.8% three-year RFS in low-risk patients. The i31-SLNB produced TN:FN ratios of 55:1 (T1–T2a) and 73:1 (T1b–T2a), exceeding the 19:1 guideline benchmark. A webcast will be held March 23, 2026, to discuss the data.